Biotechnology

Exact Sciences

Abbott Exceeds Q1 Earnings Estimates, Announces $23B Precision Biosciences Acquisition

Precision Science Shareholders Approve Abbott's Acquisition Deal at $105 per Share in Cash

Exact Sciences and Abbott Merger Approved

Exact Sciences released FY2025 earnings on February 13 (EST), actual revenue USD 3.247 B (forecast USD 3.229 B), actual EPS USD -1.102 (forecast USD -0.6296)

Exact Sciences released FY2025 Q4 earnings on February 13 (EST), actual revenue USD 878.38 M (forecast USD 860.76 M), actual EPS USD -0.453 (forecast USD -0.0638)

Precision Science Schedules Virtual Shareholder Meeting to Vote on Abbott Merger Proposal

Precision Sciences' Alert of Sale to Abbott Released by Law Firm by Mistake and Withdrew

EXACT Sciences to hold special shareholders' meeting to vote on Abbott merger

Precision Sciences Launches CRANE Study with First Participant Recruitment in Japan

Abbott Announces $21 Billion Acquisition of Alere to Enhance Diagnostic Business

Abbott Acquires Exact Sciences for $21 Billion in Cash

Jefferies Downgrades Exact Sciences Rating While Upgrading Price Target

EXAS Shares Gap Up, Executives Sell Stocks

Abbott Announces Acquisition of Precipio for Approximately $21 Billion

Precision Sciences Obtains Exclusive License for Freenome Blood-based Colorectal Cancer Screening Test

FactSet Survey: Analysts Raise Precision Biosciences Target Price Estimate

EXACT Sciences Corporation Executives Brian Baranick Sell Common Stock

Guggenheim Raises Precision Scientific's Target Price to $75

Precision Science Faces Major Regulatory Risks

Exact Sciences released FY2025 Q3 earnings on November 3 After-Market (EST), actual revenue USD 0 (forecast USD 810.55 M), actual EPS USD 0 (forecast USD -0.0858)

OPTIMI HEALTH CORP

FLAG SHIP ACQUISITION CORPORATION COM USD0.001 (SUB/RIGHT 31/03/2026)

GCL Global

HCW Biologics

Silexion Therapeutics

Micware

MetaVia

BiomX

EMMIS ACQUISITION CORP. ORD USD0.0001 (S/R 12/09/2030)

HORIZON SPACE ACQUISITION II CORP COM USD0.0001 30/03/2026(SUB/RIGHTS)

EXAS

Abbott Laboratories recently completed a $21 billion acquisition of Exact Sciences, aiming to enhance its cancer diagnostics capabilities. Despite exceeding Q1 2026 sales and earnings expectations, Abbott faces significant legal challenges related to infant formula and securities litigation. The integration of Exact Sciences may lead to short-term earnings dilution, impacting investor sentiment. Analysts project Abbott's revenue could reach $59.7 billion by 2029, suggesting a potential 40% upside in stock value, but legal risks remain a concern for shareholders.

Simplywall

Abbott Laboratories

iShares US Medical Devices

Health Care Select Sector SPDR

SPDR S&P Health Equip

Exact Sciences Deal and Legal Pressures Might Change The Case For Investing In Abbott (ABT)

LABU

SBIO

ARKG

Abbott Laboratories (NYSE:ABT) reported strong Q1 earnings but lowered its 2026 outlook, citing dilution from the Exact Sciences acquisition. Q1 sales reached $11.16 billion, surpassing expectations, with adjusted earnings of $1.15 per share. However, the company revised its 2026 earnings forecast down to $5.38-$5.58 per share, below Wall Street's consensus. Analysts have adjusted their price targets for Abbott, with several maintaining a Buy rating but lowering targets to $120. Abbott shares fell 0.1% to close at $95.47.

benzinga_article

Invesco Biotechnology & Genome ETF

Direxion S&P Biotech Bull 3X

SPDR S&P Biotech

iShares US Healthcare Providers

VanEck Biotech ETF

iShares US Pharma

ALPS Medical Breakthrough

iShares Global Healthcare

Proshares Ultra Nasdaq Biotech

VG Health

iShares Biotechnology ETF

iShares Genomics Immunology and Healthcare ETF

Ark Genomic Revolution ETF

First Trust NYSE Arca Biotech Index Fd

Stifel Financial

Bank of America

Evercore

STIFEL FINANCIAL CORP 6.125% DEP SHS REP 1/1000 NON CU PF SR C

Stifel Financial Pref Share SFB 5.2 10/15/47

STIFEL FINANCIAL CORP 6.25%NON CUM DEP SHS REP 1/1000TH SER B

STIFEL FINANCIAL CORP 4.50% DEP SHS REP 1/1000TH PREF SHS SR D

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH INT NON CUM PFD QQ

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '5'

BANK OF AMERICA CORPORATION 7.25% NON-CUM PERP CONV PFD SER L

BANK OF AMERICA CORPORATION 5.875%NON CUM DEP SHS REP1/1000TH SER HH

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '2'

BANK OF AMERICA CORPORATION 5% DEP SHS REPR 1/1000TH NON CUM PFD LL

BANK OF AMERICA CORPORATION DEP SHARES REP 1/1000TH PERP PFD SER 'E'

BANK OF AMERICA CORPORATION INCOME CAPITAL OBLIG NTS DUE 15/12/2066

BANK OF AMERICA CORPORATION 4.375% DP SH RP 1/1000TH IN NON CU PF NN

BANK OF AMERICA CORPORATION DEP SH REP 1/1200TH PRF SER 1 USD25

BANK OF AMERICA CORPORATION 5.375%DEP SHS REP 1/1000TH NON CUM SR KK

BANK OF AMERICA CORPORATION 6%NON CUM DEP SHS EACH REP 1/1000 SER GG

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200 PFD SER 4 USD25

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH NON CUM PFD SER SS

BANK OF AMERICA CORPORATION 4.125%DEP SH REP 1/1000 PFD SER PP USD25

Bank of America Corp

Abbott Laboratories Analysts Slash Their Forecasts After Q1 Earnings

Abbott Laboratories held its Q1 earnings call, highlighting steady growth and strong device momentum despite near-term pressures. Adjusted EPS reached $1.15, with Q2 guidance of $1.25–$1.31. The Exact Sciences acquisition is expected to add $3 billion in sales, while medical devices showed 8.5% growth. Continuous glucose monitoring generated $2 billion in revenue. However, rapid diagnostics faced a 10% decline due to weak respiratory testing. Overall, Abbott maintains a 6.5%–7.5% sales growth outlook for 2026, despite challenges in China and EPS dilution from acquisitions.

Tip Ranks

Abbott Laboratories Bets on Devices in 2026 Call

Abbott (ABT) Q1 sales fell; rapid and molecular diagnostics down 7.4% to $812M, weaker nutrition and diabetes device sales, heart devices lost share to Edwards. Shares fell ~4–6% after outlook cut.1Abbott Laboratories (ABT) Q1 CY2026 adjusted EPS $1.15, in line with estimates. Full-year adjusted EPS guidance cut to $5.48 midpoint, a 3.4% reduction from prior outlook.2Abbott (ABT) says Exact Sciences deal boosted its oncology diagnostics and helped growth; Medical Devices and Established Pharmaceuticals segments showed solid performance.3

TradingView

Edwards Lifesciences

Key facts: Abbott Q1 diagnostics -7.4%; guidance cut; Exact Sciences

Abbott reported Q1 2026 results with revenue of $11.16 billion and adjusted diluted EPS of $1.15, a 6% increase year-over-year. The company completed its acquisition of Exact Sciences on March 23, 2026, and updated its 2026 guidance to 6.5%-7.5% sales growth and adjusted EPS of $5.38-$5.58. Abbott declared a quarterly dividend of $0.63 per share. Segment performance included a 9% growth in Established Pharmaceuticals and 8.5% in Medical Devices, while Nutrition saw a decline of 7.7%.

Direxion S&P Biotech Bear 3X

Abbott reports Q1 2026: Revenue $11.16B, adjusted diluted EPS $1.15; updates 2026 guidance

Abbott Laboratories (ABT) opened down 4.34% amid a 3.44% decline in the Healthcare Services & Equipment sector. The drop is attributed to a revised earnings outlook, lowering its 2026 EPS guidance due to the acquisition of Exact Sciences, which is expected to dilute earnings. Despite surpassing revenue forecasts, Q1 2026 results showed mixed performance, with ongoing legal risks from lawsuits related to its infant formula impacting brand perception. Analysts have adjusted price targets downwards, contributing to cautious investor sentiment, although the overall consensus remains positive.

TradingKey

Hims & Hers Health

Danaher

Abbott Laboratories Stock (ABT) Opened Down by 4.34% on Apr 16: What Investors Need To Know

Abbott Laboratories has lowered its annual profit forecast following a $21 billion acquisition of cancer-screening company Exact Sciences, aimed at revitalizing its struggling diagnostics business. The company now anticipates adjusted earnings of $5.38 to $5.58 per share, down from a previous estimate of $5.55 to $5.80. Abbott's shares fell 3.8% in pre-market trading, reflecting a 19% decline over the past year. Despite challenges, Abbott projects a 6.5% to 7.5% sales growth for 2026 and reported first-quarter sales of $11.2 billion, slightly exceeding expectations.

Businesstimes News

Abbott cuts profit forecast in wake of cancer-screening deal

Abbott (ABT) has updated its FY26 guidance, projecting adjusted EPS of $5.38 to $5.58, factoring in a $0.20 dilution from the acquisition of Exact Sciences. The company anticipates comparable sales growth of 6.5% to 7.5% for the year and expects second-quarter adjusted diluted EPS between $1.25 and $1.31. CEO Robert B. Ford emphasized that the acquisition enhances Abbott's growth potential. Following the announcement, Abbott shares fell 4.3% to $97.18 in pre-market trading.

nasdaq

Nasdaq

Abbott Updates FY26 Guidance To Reflect Acquisition Of Exact Sciences

Exact Sciences(EXAS.US)